In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation
Dhaya Seshasayee, … , Sarah G. Hymowitz, Flavius Martin
Dhaya Seshasayee, … , Sarah G. Hymowitz, Flavius Martin
Published December 3, 2007
Citation Information: J Clin Invest. 2007;117(12):3868-3878. https://doi.org/10.1172/JCI33559.
View: Text | PDF
Research Article

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation

Abstract

Thymic stromal lymphopoietin (TSLP) potently induces deregulation of Th2 responses, a hallmark feature of allergic inflammatory diseases such as asthma, atopic dermatitis, and allergic rhinitis. However, direct downstream in vivo mediators in the TSLP-induced atopic immune cascade have not been identified. In our current study, we have shown that OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. Treating mice with OX40L-blocking antibodies substantially inhibited immune responses induced by TSLP in the lung and skin, including Th2 inflammatory cell infiltration, cytokine secretion, and IgE production. OX40L-blocking antibodies also inhibited antigen-driven Th2 inflammation in mouse and nonhuman primate models of asthma. This treatment resulted in both blockade of the OX40-OX40L receptor-ligand interaction and depletion of OX40L-positive cells. The use of a blocking, OX40L-specific mAb thus presents a promising strategy for the treatment of allergic diseases associated with pathologic Th2 immune responses.

Authors

Dhaya Seshasayee, Wyne P. Lee, Meijuan Zhou, Jean Shu, Eric Suto, Juan Zhang, Laurie Diehl, Cary D. Austin, Y. Gloria Meng, Martha Tan, Sherron L. Bullens, Stefan Seeber, Maria E. Fuentes, Aran F. Labrijn, Yvo M.F. Graus, Lisa A. Miller, Edward S. Schelegle, Dallas M. Hyde, Lawren C. Wu, Sarah G. Hymowitz, Flavius Martin

×

Figure 1

α-mOX40L mAb blocks TSLP-induced inflammation in lung.

Options: View larger image (or click on image) Download as PowerPoint
α-mOX40L mAb blocks TSLP-induced inflammation in lung. (A) Experimental ...
(A) Experimental design for TSLP-induced lung inflammation. BALB/c mice (n = 8/group) were administered 500 ng TSLP (or control PBS) intranasally on days 0, 1, and 2. Mice were treated with 150 μg control mIgG2a, wild-type α-OX40L 4F5, or 4F5-DANA mAbs intraperitoneally on days 0, 2, 5, 8, and 12 and sacrificed on day 13. Numbers of BALF lymphocytes and eosinophils on day 13 (B) and total IgE levels in serum on day 13 (C) are quantified. (D) Levels of IL-4, IL-5, and IL-13 in the BALF were measured by ELISA. Results are the mean number of cells ± SD. *P < 0.01 (Dunnett’s test). One representative of 3 experiments is shown.